Bavarian Nordic presents new preclinical data for Covid-19 vaccine
Bavarian Nordic's first clinical studies with a vaccine for Covid-19 are almost ready. Ahead of launch, the firm has received a batch of positive preclinical data. This confirms the potential, according to Bavarian Nordic's CEO Paul Chaplin.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Read this article for free
Register with your E-mail. No credit card required.